Is BridgeBio Pharma, Inc. overvalued or undervalued?

As of 7 November 2019, the valuation grade for BridgeBio Pharma, Inc. moved from does not qualify to risky. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -4.59, an EV to EBIT of -13.70, and an EV to EBITDA of -13.82. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have fair valuations with P/E ratios of 19.09 and 15.17, respectively, highlighting the relative overvaluation of BridgeBio.
Despite its overvaluation, BridgeBio has shown strong stock performance, with a year-to-date return of 94.35%, significantly outperforming the S&P 500's return of 12.22% over the same period. However, the company's negative return on capital employed (ROCE) of -419.24% and the overall risky classification suggest caution for potential investors.